{
    "clinical_study": {
        "@rank": "104270", 
        "arm_group": {
            "arm_group_label": "Myfortic", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "This is a single-center, prospective, open label study in islet transplant recipients after\n      complete islet graft rejection/loss, defined as stimulated c-peptide \u22640.3 ng/mL. After\n      complete islet graft loss is determined, patient's maintenance immunosuppression (i.e.\n      sirolimus and tacrolimus) will be discontinued and they will be placed on Myfortic\u00ae\n      monotherapy for 2 years thereafter. After completion of two years of Myfortic\u00ae maintenance\n      monotherapy, it will be weaned and subjects will be monitored over the subsequent twelve\n      months, for the appearance of sensitization using panel reactive antibody (PRA) levels."
        }, 
        "brief_title": "Myfortic\u00ae Monotherapy to Prevent de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss", 
        "condition": [
            "Type 1 Diabetes Mellitus", 
            "Allosensitization After Transplant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female patients age 18-70 years of age.\n\n          2. Ability to provide written informed consent.\n\n          3. Mentally stable and able to comply with the procedures of the study protocol.\n\n          4. Any subject currently prescribed immunosuppressive medications or discontinuation of\n             immunosuppressive medications indicated as per current protocol of islet\n             transplantation.\n\n          5. History of at least one islet transplant.\n\n          6. Stimulated C-peptide <0.3 ng/ml.\n\n        Exclusion Criteria:\n\n          1. Known history of untreated severe hyperlipidemia, obesity, or refractory hypertension\n\n          2. For female participants: Positive pregnancy test or presently breast-feeding.\n\n          3. History of active infection including hepatitis B, hepatitis C, HIV, or TB.\n\n          4. Any history of malignancy except for completely resected squamous or basal skin cell\n             carcinoma.\n\n          5. Known active alcohol or substance abuse.\n\n          6. Severe co-existing history of cardiac disease, characterized by a history of any one\n             of these conditions: recent myocardial infarction (within past 6 months), evidence of\n             ischemia on functional cardiac exam within the last year, or left ventricular\n             ejection fraction <30%.\n\n          7. History of persistent elevation of liver function tests. SGOT (AST), SGPT (ALT),\n             alkaline phosphatase or total bilirubin, with values >1.5 times normal upper limits\n             will exclude a patient.\n\n          8. Evidence of inter-current infection.\n\n          9. Active peptic ulcer disease\n\n         10. History on non-adherence to prescribed regimens including immunosuppression.\n\n         11. PRA \u2265 50% or evidence of significant sensitization to be determined at discretion of\n             the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999361", 
            "org_study_id": "20071058"
        }, 
        "intervention": {
            "arm_group_label": "Myfortic", 
            "intervention_name": "Myfortic", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolic Acid", 
                "Mycophenolate mofetil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 25, 2013", 
        "link": {
            "url": "http://www.diabetesresearch.org/diabetes-clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "islet@med.miami.edu", 
                "last_name": "Rodolfo Alejandro, MD", 
                "phone": "305-243-5321"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "Diabetes Research Institute"
            }, 
            "investigator": {
                "last_name": "Rodolfo Alejandro, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: UM Medical Sciences IRB C", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Allosensitization after complete islet graft loss after completion of two years of Myfortic\u00ae maintenance monotherapy.", 
            "measure": "allosensitization after complete islet graft loss", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999361"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Miami", 
            "investigator_full_name": "Rodolfo Alejandro", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of Miami", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rodolfo Alejandro", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}